A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
暂无分享,去创建一个
Terry M Therneau | Robert A Kyle | T. Therneau | L. Melton | L. Melton | R. Kyle | D. Larson | S. Rajkumar | M. Plevak | S Vincent Rajkumar | L Joseph Melton | Dirk R Larson | L. J. Melton | Janice R Offord | Matthew F Plevak | R. Kyle | J. Offord
[1] A. López-Guillermo,et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance , 1992, British journal of haematology.
[2] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[3] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[4] U. Axelsson,et al. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. , 2009, Acta medica Scandinavica.
[5] M. Vicariot,et al. Monoclonal gammopathies in the adult population of Finistère, France. , 1982, Journal of clinical pathology.
[6] R. Kyle,et al. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. , 1978, The American journal of medicine.
[7] A. Linos,et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. , 1992, Blood.
[8] L. Melton,et al. The threat to medical-records research. , 1997, The New England journal of medicine.
[9] D. Cox. Regression Models and Life-Tables , 1972 .
[10] L. Elveback,et al. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. , 1972, Blood.
[11] R A Kyle,et al. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.
[12] L. Melton,et al. History of the Rochester Epidemiology Project. , 1996, Mayo Clinic proceedings.
[13] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[14] G Berry,et al. The analysis of mortality by the subject-years method. , 1983, Biometrics.
[15] L. Baldini,et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. , 1996, Blood.
[16] J. Hällén. Discrete gammaglobulin (M-)components in serum. Clinical study of 150 subjects without myelomatosis. , 1966, Acta medica Scandinavica. Supplementum.
[17] J. Coebergh,et al. Malignant transformation of monoclonal gammopathy of undetermined significance among out‐patients of a community hospital in Southeastern Netherlands , 1995, British journal of haematology.